Enterprise Value
2.316B
Cash
527.7M
Avg Qtr Burn
-27.77M
Short % of Float
8.05%
Insider Ownership
6.24%
Institutional Own.
78.34%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SGR-1505 (MALT1 inhibitor) Details Cancer, B-cell malignancies | Phase 1 Data readout |